PT  - JOURNAL ARTICLE
AU  - Kirov, Stefan
TI  - Association Between BCG Policy is Significantly Confounded by Age and is Unlikely to Alter Infection or Mortality Rates
AID  - 10.1101/2020.04.06.20055616
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.06.20055616
4099  - http://medrxiv.org/content/early/2020/04/11/2020.04.06.20055616.short
4100  - http://medrxiv.org/content/early/2020/04/11/2020.04.06.20055616.full
AB  - Recently a number of publications looked at the association between COVID-19 morbidity and mortality on one hand and countries’ policies with respect to BCG vaccination on the other. This connection arises from differences in the rates of infection in countries where BCG vaccination is mandatory compared to countries where mandatory vaccination no longer exists or was never implemented in the first place. In at least 2 preprint publications the authors expressed the view that the “known immunological benefits” of BCG vaccination may be behind the biological mechanism of such observation.One study accounted for different income levels in different groups. Another study did not attempted to do so, instead exploring the differences between countries where a booster shot is given vs others where no such practice exists (finding no connection).Both of these studies did not explore other potential confounding factors. Meanwhile the press has focused on these headlines and pushed the narrative that BCG vaccination is causally linked to infection and mortality rates. This poses a serious challenge, demonstrated by the recently initiated clinical trials on BCG vaccination within the COVID19 context.This study shows that population age is a very significant confounding factor that explains the rates of infections much better and has a solid biology mechanism which explains this correlation. It suggests that BCG vaccination may have little or no causal link to infection rates and advises that any follow up studies should control for several confounding factors, such as population age, ethnicity, rates of certain chronic diseases, time from community spread start date, major public policy decisions and income levels.Competing Interest StatementStefan Kirov is an employee of Bristol Myers Squibb. This research was done with no BMS support or involvement, therefore this notice is simply to inform that the author receives compensation as an employee.Funding StatementNo fundingAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is readily available from public sources. Processed data has been also made available. https://github.com/kirovsa/covid19-bcg